Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The dipyridodiazepinone Nevirapine is a potent and highly specific inhibitor of the reverse transcriptase (RT) from human immunodeficiency virus type 1 (HIV-1). It is a member of an important class of nonnucleoside drugs that appear to share part or all of the same binding site on the enzyme but are susceptible to a variety of spontaneous drug-resistance mutations. The co-crystal-structure of HIV-1 RT and Nevirapine has been solved previously at 3.5-A resolution and now is partially refined against data extending to 2.9-A spacing. The drug is bound in a hydrophobic pocket and in contact with some 38 protein atoms from the p66 palm and thumb subdomains. Most, but not all, nonnucleoside drug-resistance mutations map to residues in close contact with Nevirapine. The major effects of these mutations are to introduce steric clashes with the drug molecule or to remove favorable protein-drug contacts. Additionally, four residues (Phe-227, Trp-229, Leu-234, and Tyr-319) in contact with Nevirapine have not been selected as sites of drug-resistance mutations, implying that there may be limitations on the number and types of resistance mutations that yield viable virus. Strategies of inhibitor design that target interactions with these conserved residues may yield drugs that are less vulnerable to escape mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914
Self-citationMultiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)
Larder, B. A., & Kemp, S. D. (1989) · Science · doi:10.1126/science.2479983 · Cited by 1,163
Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., et al. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6320 · Cited by 1,115
Structural invariants in protein folding
Chothia, C. (1975) · Nature · doi:10.1038/254304a0 · Cited by 869
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M. J., Breslin, H. J., Raeymaeckers, A., Gelder, J. V., Woestenborghs, R., Heykants, J., et al. (1990) · Nature · doi:10.1038/343470a0 · Cited by 756
Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor
Merluzzi, V. J., Hargrave, K. D., Labadia, M., Grozinger, K., Skoog, M., Wu, J. C., Shih, C.-K., Eckner, K., Hattox, S., Adams, J., et al. (1990) · Science · doi:10.1126/science.1701568 · Cited by 743
Molecular Targets for AIDS Therapy
Mitsuya, H., Yarchoan, R., & Broder, S. (1990) · Science · doi:10.1126/science.1699273 · Cited by 732
Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase
St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., & Larder, B. A. (1991) · Science · doi:10.1126/science.1716788 · Cited by 679
Slow-cooling protocols for crystallographic refinement by simulated annealing
Brünger, A. T., Krukowski, A., & Erickson, J. W. (1990) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390002355 · Cited by 517
Cited by
Recent Advances in Zinc Enzymology
Lipscomb, W. N., & Sträter, N. (1996) · Chemical Reviews · doi:10.1021/cr950042j · Cited by 1,366
Implications of protein flexibility for drug discovery
Teague, S. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1129 · Cited by 755
“The site for HIV-RT inhibitors, such as nevirapine (9), is 10 A from the active sit”
BackgroundTwo‐Metal Ion Catalysis in Enzymatic Acyl‐ and Phosphoryl‐Transfer Reactions
Sträter, N., Lipscomb, W. N., Klabunde, T., & Krebs, B. (1996) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199620241 · Cited by 611
High resolution structures of HIV-1 RT from four RT–inhibitor complexes
Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D., et al. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-293 · Cited by 502
Young, S. D., Britcher, S. F., Tran, L. O., Payne, L. S., Lumma, W. C., Lyle, T. A., Huff, J. R., Anderson, P. S., Olsen, D. B., & Carroll, S. S. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2602 · Cited by 482
Structural biology of HIV 1 1Edited by P. E. Wright
Turner, B. G., & Summers, M. F. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2354 · Cited by 470
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
Esnouf, R., Ren, J., Ross, C., Jones, Y., Stammers, D., & Stuart, D. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-303 · Cited by 442
Crystal Structure of a pol α Family Replication DNA Polymerase from Bacteriophage RB69
Wang, J., Sattar, A. K. M. A., Wang, C. C., Karam, J. D., Konigsberg, W. H., & Steitz, T. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80296-2 · Cited by 432
Self-citationde Béthune, M.-P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.008 · Cited by 401
The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.
Rodgers, D. W., Gamblin, S. J., Harris, B. A., Ray, S., Culp, J. S., Hellmig, B., Woolf, D. J., Debouck, C., & Harrison, S. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.1222 · Cited by 378
Hopkins, A. L., Ren, J., Esnouf, R. M., Willcox, B. E., Jones, E. Y., Ross, C., Miyasaka, T., Walker, R. T., Tanaka, H., Stammers, D. K., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960056x · Cited by 346
Ding, J., Das, K., Hsiou, Y., Sarafianos, S. G., Clark, A. D., Jacobo-Molina, A., Tantillo, C., Hughes, S. H., & Arnold, E. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2208 · Cited by 321
Bangsberg, D. R., Acosta, E. P., Gupta, R., Guzman, D., Riley, E. D., Harrigan, P. R., Parkin, N., & Deeks, S. G. (2006) · AIDS · doi:10.1097/01.aids.0000199825.34241.49 · Cited by 312
Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P. A. J., Hughes, S. H., & Arnold, E. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0595-407 · Cited by 298
Hsiou, Y., Ding, J., Das, K., Clark, Jr., Hughes, S., & Arnold, E. (1996) · Structure · doi:10.1016/s0969-2126(96)00091-3 · Cited by 289
Barry, M., Mulcahy, F., Merry, C., Gibbons, S., & Back, D. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936040-00004 · Cited by 275
Bacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2475-2484.2000 · Cited by 268
Wang, J., Smerdon, S. J., Jäger, J., Kohlstaedt, L. A., Rice, P. A., Friedman, J. M., & Steitz, T. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7242 · Cited by 175
Self-citationJones, R. B., Garrison, K. E., Wong, J. C., Duan, E. H., Nixon, D. F., & Ostrowski, M. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001547 · Cited by 99
HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review
Bradshaw, D., & Taylor, G. P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.881547 · Cited by 12
“This may reflect the greater sequence diversity in RT at the NNRTI-binding pocket than at the substrate-binding site, and the dependence of NNRTI binding on RT structure (120, 121).”
Background
Metadata
- Authors
- Smerdon, S. J., Jäger, J., Wang, J., Kohlstaedt, L. A., Chirino, A. J., Friedman, J. M., Rice, P. A., & Steitz, T. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-04-26
- Volume
- 91
- Issue
- 9
- Pages
- 3911-3915
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2126644478
- Cited by
- 331
- References
- 27
- FWCI
- 23.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.